Salipro Biotech AB
Peter Jahnmatz has extensive experience in business development and key account management in the biotech industry. Peter has a background in immunology, molecular biology, and psychology, with a focus on studying memory B cell immunity against diseases like Malaria. Additionally, Peter has experience in photography and writing for an international web-based magazine covering entertainment.
This person is not in any teams
Salipro Biotech AB
Making the undruggable druggable. Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. Headquartered in Stockholm, Sweden, the company collaborates with global pharma and biotech companies to accelerate the discovery of novel drugs. For our own pipeline, we are striving to develop drugs toward targets that no one could access before. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design.